Lexicon Pharmaceuticals Inc. recently presented its two sotagliflozin studies, inTandem1 and inTandem2, at the 77th American Diabetes Association Scientific Sessions in San Diego, California.
“We are extremely pleased with the results achieved by sotagliflozin in its three Phase 3 studies,” Lonnel Coats, Lexicon’s president and CEO, said. “We look forward to seeing the pooled continuous glucose monitoring data from inTandem1 and inTandem2 as well as data from secondary endpoints in inTandem2 in the third quarter.”
The two studies covered 24 weeks of data analyzing the drug in patients with Type 1 diabetes. In both studies, the drug helped reduce A1C when compared to a placebo. Additionally, the drug was well tolerated by patients.
“There remains a need for oral therapeutic agents in addition to insulin to help improve quality of life in patients with Type 1 diabetes by reducing the diabetes management burden and sotagliflozin has that potential,” lead investigator Dr. John Buse said in a statement. “Sotagliflozin has demonstrated, in three Phase 3 studies, the ability for patients to achieve glycemic goals with a safety profile that supports its utility in the Type 1 diabetes community.”
Alerts Sign-up